Profusa Inc sees significant pre-market gains amid market strength
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 15 Dec 25
Source: Coinmarketcap
Profusa Inc's stock has surged by 16.46% in pre-market trading, crossing above the 5-day SMA, reflecting strong investor interest.
This price movement is attributed to broad market strength, with the Nasdaq-100 up 0.55% and the S&P 500 up 0.48%. The positive sentiment in the market has likely contributed to the stock's upward momentum, suggesting a favorable environment for growth.
The implications of this surge indicate a potential shift in investor focus towards biotech companies, as broader market trends favor sectors that show resilience and growth potential.
Analyst Views on PFSA
About PFSA
Profusa, Inc. is a commercial stage digital health company. The Company is engaged in the development of a new generation of biointegrated sensors that potentially empower the individual with the ability to monitor their body chemistry. The Company’s technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. Its first clinical offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels in various regions of interest, both acutely and long-term. The Lumee Oxygen Platform has been designed for use in applications where monitoring of compromised tissue is beneficial, such as peripheral artery disease that results in narrowing of blood vessels and reduced blood flow to the lower limbs; chronic wounds (diabetic ulcers, pressure sores) that do not heal properly; and reconstructive surgery.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
